Positive Phase 3 Results for Foundayo in Diabetes Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy LLY?
Source: stocktwits
- Cardiovascular Event Risk Reduction: In a study involving over 2,700 adults with type 2 diabetes, patients taking Foundayo experienced a 16% lower risk of major adverse cardiovascular events compared to those on insulin glargine, indicating Foundayo's significant advantage in cardiovascular safety, which may attract more patients to choose this medication.
- Significant Mortality Risk Reduction: A pre-planned analysis revealed that patients on Foundayo had a 57% lower risk of death from any cause compared to those on insulin glargine, further enhancing Foundayo's appeal as a diabetes treatment and potentially increasing its market acceptance.
- FDA Submission Plans: Based on the trial results, Eli Lilly plans to submit an application for Foundayo's approval to the FDA by the end of Q2, which, if approved, could open new market opportunities for the company in diabetes treatment and strengthen its product portfolio.
- Market Competition Dynamics: Despite the positive clinical results for Foundayo, retail investor sentiment towards Eli Lilly remains bearish, likely due to intense competition in the weight-loss drug market, particularly from Novo Nordisk, which may affect investor confidence in the company's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 903.990
Low
950.00
Averages
1192
High
1500
Current: 903.990
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's GLP-1 Drug Sales Surge Remarkably
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, showcasing the company's strong performance in the rapidly growing weight-loss drug market and further solidifying its market leadership.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, although its current P/E ratio of 39x remains above the industry average.
- Intensifying Competitive Risks: Despite Eli Lilly's leading position in the GLP-1 space, competitors like Novo Nordisk and Pfizer are actively launching new products, which could erode Eli Lilly's market share, especially as patents expire and generics emerge, potentially impacting revenues significantly.
- Strategic Acquisition Moves: To address future competition and risks, Eli Lilly is leveraging the windfall from its GLP-1 success to pursue strategic acquisitions, which may help diversify its product pipeline, but the uncertainty surrounding the success of these new drugs could affect the company's long-term growth potential.
See More
ELI LILLY IN FINAL DISCUSSIONS TO PURCHASE KELONIA THERAPEUTICS FOR OVER $2 BILLION - WSJ
- Eli Lilly's Acquisition Talks: Eli Lilly is engaged in advanced discussions to acquire Kelonia Therapeutics.
- Financial Implications: The potential acquisition is valued at over $2 billion.
See More
ELI LILLY CLOSES IN ON AGREEMENT WITH CANCER BIOTECH FIRM - WSJ
Eli Lilly's Cancer Deal: Eli Lilly has reached a significant agreement in the cancer biotechnology sector, indicating a strategic move to enhance its portfolio in oncology treatments.
Impact on Biotechnology: This deal is expected to influence the biotechnology landscape, potentially leading to advancements in cancer therapies and improved patient outcomes.
Market Reactions: The announcement has garnered attention from investors and analysts, reflecting optimism about Eli Lilly's future growth and innovation in cancer treatment.
Future Developments: Further details on the specifics of the deal and its implications for Eli Lilly's research and development efforts are anticipated in upcoming reports.
See More
Indian Regulators Seize Counterfeit Mounjaro Pens Amid Drug Safety Concerns
- Counterfeit Drug Seizure: Indian regulators in Haryana seized over 500 suspected counterfeit Mounjaro pens from a vehicle near New Delhi, highlighting serious concerns over drug safety and regulatory enforcement.
- Accused Lacked License: The primary accused did not possess a pharmaceutical license and manufactured the counterfeit drugs at a private property, indicating significant regulatory gaps and market risks.
- Significant Market Impact: Mounjaro has become India's top-selling drug by value, with the obesity market projected to reach 80 billion rupees ($859.38 million) by 2030, and counterfeit issues could harm brand reputation and market share.
- Intense Price Competition: The arrested individuals sold the counterfeit pens on IndiaMART at a 27% discount to the genuine product, exacerbating price competition and increasing consumer risks in the market.
See More
Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion
- Acquisition Talks Progress: Eli Lilly is in advanced discussions to acquire Kelonia Therapeutics, a private biotech firm based in Cambridge, Massachusetts, for over $2 billion, with a potential announcement as soon as Monday, although the talks could still collapse.
- Milestone Payment Terms: The deal's price may include additional milestone-based payments contingent on Kelonia achieving specific targets, indicating Lilly's recognition of Kelonia's future potential and strategic value.
- Stock Price Fluctuations: As of April 17, Lilly's stock closed at $927.03, up $23.04 or 2.55%, but slipped to $921.50 in after-hours trading, down $5.53 or 0.60%, reflecting market volatility amid acquisition speculation.
- Market Reaction: Despite the acquisition talks not being finalized, the market's positive response to Lilly's stock indicates investor confidence in its expansion into the biotech sector, potentially enhancing its competitive position in the biopharmaceutical market.
See More
Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion
- Acquisition Negotiations: Eli Lilly is in advanced discussions to acquire Kelonia Therapeutics for over $2 billion, with an announcement possible as soon as Monday, which would significantly enhance Lilly's competitive position in the $240 billion global oncology market.
- Innovative Treatment Potential: Kelonia is focused on developing a next-generation CAR-T therapy that aims to simplify the treatment process by eliminating the need for chemotherapy and custom manufacturing steps, potentially reshaping the treatment landscape for multiple myeloma if successful.
- Financial Background: Kelonia was last valued at slightly above $100 million in April 2022 and has raised nearly $60 million to date; the acquisition would provide Lilly with a new revenue stream and further diversify its cancer drug portfolio, particularly in the blood cancer segment.
- Strategic Expansion: This acquisition aligns with Lilly's recent deals, including the $6.3 billion acquisition of Centessa Pharmaceuticals, demonstrating the company's proactive approach in the rapidly growing biopharmaceutical sector, leveraging cash flow from its obesity and diabetes drugs to accelerate M&A activities.
See More
Eli Lilly's GLP-1 Drug Sales Surge Remarkably
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, showcasing the company's strong performance in the rapidly growing weight-loss drug market and further solidifying its market leadership.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, although its current P/E ratio of 39x remains above the industry average.
- Intensifying Competitive Risks: Despite Eli Lilly's leading position in the GLP-1 space, competitors like Novo Nordisk and Pfizer are actively launching new products, which could erode Eli Lilly's market share, especially as patents expire and generics emerge, potentially impacting revenues significantly.
- Strategic Acquisition Moves: To address future competition and risks, Eli Lilly is leveraging the windfall from its GLP-1 success to pursue strategic acquisitions, which may help diversify its product pipeline, but the uncertainty surrounding the success of these new drugs could affect the company's long-term growth potential.
See More
ELI LILLY IN FINAL DISCUSSIONS TO PURCHASE KELONIA THERAPEUTICS FOR OVER $2 BILLION - WSJ
- Eli Lilly's Acquisition Talks: Eli Lilly is engaged in advanced discussions to acquire Kelonia Therapeutics.
- Financial Implications: The potential acquisition is valued at over $2 billion.
See More
ELI LILLY CLOSES IN ON AGREEMENT WITH CANCER BIOTECH FIRM - WSJ
Eli Lilly's Cancer Deal: Eli Lilly has reached a significant agreement in the cancer biotechnology sector, indicating a strategic move to enhance its portfolio in oncology treatments.
Impact on Biotechnology: This deal is expected to influence the biotechnology landscape, potentially leading to advancements in cancer therapies and improved patient outcomes.
Market Reactions: The announcement has garnered attention from investors and analysts, reflecting optimism about Eli Lilly's future growth and innovation in cancer treatment.
Future Developments: Further details on the specifics of the deal and its implications for Eli Lilly's research and development efforts are anticipated in upcoming reports.
See More
Indian Regulators Seize Counterfeit Mounjaro Pens Amid Drug Safety Concerns
- Counterfeit Drug Seizure: Indian regulators in Haryana seized over 500 suspected counterfeit Mounjaro pens from a vehicle near New Delhi, highlighting serious concerns over drug safety and regulatory enforcement.
- Accused Lacked License: The primary accused did not possess a pharmaceutical license and manufactured the counterfeit drugs at a private property, indicating significant regulatory gaps and market risks.
- Significant Market Impact: Mounjaro has become India's top-selling drug by value, with the obesity market projected to reach 80 billion rupees ($859.38 million) by 2030, and counterfeit issues could harm brand reputation and market share.
- Intense Price Competition: The arrested individuals sold the counterfeit pens on IndiaMART at a 27% discount to the genuine product, exacerbating price competition and increasing consumer risks in the market.
See More
Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion
- Acquisition Talks Progress: Eli Lilly is in advanced discussions to acquire Kelonia Therapeutics, a private biotech firm based in Cambridge, Massachusetts, for over $2 billion, with a potential announcement as soon as Monday, although the talks could still collapse.
- Milestone Payment Terms: The deal's price may include additional milestone-based payments contingent on Kelonia achieving specific targets, indicating Lilly's recognition of Kelonia's future potential and strategic value.
- Stock Price Fluctuations: As of April 17, Lilly's stock closed at $927.03, up $23.04 or 2.55%, but slipped to $921.50 in after-hours trading, down $5.53 or 0.60%, reflecting market volatility amid acquisition speculation.
- Market Reaction: Despite the acquisition talks not being finalized, the market's positive response to Lilly's stock indicates investor confidence in its expansion into the biotech sector, potentially enhancing its competitive position in the biopharmaceutical market.
See More
Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion
- Acquisition Negotiations: Eli Lilly is in advanced discussions to acquire Kelonia Therapeutics for over $2 billion, with an announcement possible as soon as Monday, which would significantly enhance Lilly's competitive position in the $240 billion global oncology market.
- Innovative Treatment Potential: Kelonia is focused on developing a next-generation CAR-T therapy that aims to simplify the treatment process by eliminating the need for chemotherapy and custom manufacturing steps, potentially reshaping the treatment landscape for multiple myeloma if successful.
- Financial Background: Kelonia was last valued at slightly above $100 million in April 2022 and has raised nearly $60 million to date; the acquisition would provide Lilly with a new revenue stream and further diversify its cancer drug portfolio, particularly in the blood cancer segment.
- Strategic Expansion: This acquisition aligns with Lilly's recent deals, including the $6.3 billion acquisition of Centessa Pharmaceuticals, demonstrating the company's proactive approach in the rapidly growing biopharmaceutical sector, leveraging cash flow from its obesity and diabetes drugs to accelerate M&A activities.
See More
